Fundraising Fox

Nuo Therapeutics

OTC: AURX

Houston, US · Founded 2001 · Delaware corporation · 20 employees on LinkedIn

Nuo Therapeutics is a commercial-stage medical device company developing biodynamic therapies for wound care. Its flagship product, Aurix, is a hematogel that uses a patient's own platelets and plasma to promote healing.

BiotechHealthtechMedical Devices

Founders & leadership

DJ
David JordenExecutive
PC
Peter ClausenExecutive
MP
Martin P. RosendaleExecutive
AM
Andrew MaslanExecutive

Board

LA
Lawrence AtinskyBoard director
JD
Joseph Del GuercioBoard director
LH
Lyle HohnkeBoard director
SP
Scott PittmanBoard director
PM
Paul MintzBoard director
CE
C. Eric WinzerBoard director
JB
James BensonBoard director
MM
Mark McLoughlinBoard director

Reported raises · per SEC filings

Form D private placements

$37.2M disclosed across 10 rounds · 2012–2025

▶$791.4KraisedAug 2025 · 9 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • David JordenExecutive Officer, Director
  • Paul MintzDirector
  • Peter ClausenExecutive Officer
  • C Eric WinzerDirector
  • Scott PittmanDirector
Offering amount
$791.4K
Amount sold
$791.4K
First sale
Jul 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$849.1KraisedSep 2024 · 10 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Scott PittmanDirector
  • Paul MintzDirector
  • C Eric WinzerDirector
  • David JordenExecutive Officer, Director
  • Peter ClausenExecutive Officer
Offering amount
$849.1K
Amount sold
$849.1K
First sale
Sep 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$650.9KraisedMay 2024 · 11 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • David JordenExecutive Officer, Director
  • C Eric WinzerDirector
  • Peter ClausenExecutive Officer
  • Scott PittmanDirector
  • Paul MintzDirector
Offering amount
$650.9K
Amount sold
$650.9K
First sale
May 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$962.5KraisedDec 2023 · 9 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul MintzDirector
  • David JordenExecutive Officer, Director
  • C Eric WinzerDirector
  • Peter ClausenExecutive Officer
  • Scott PittmanDirector
Offering amount
$962.5K
Amount sold
$962.5K
First sale
Dec 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedAug 2023 · 9 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter ClausenExecutive Officer
  • C Eric WinzerDirector
  • David JordenExecutive Officer, Director
  • Paul MintzDirector
  • Scott PittmanDirector
Offering amount
$1M
Amount sold
$1M
First sale
Aug 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$407.8KraisedMay 2022 · 6 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Scott PittmanDirector
  • Paul MintZDirector
  • David JordenExecutive Officer, Director
  • C Eric WinzerDirector
  • Peter ClausenExecutive Officer
Offering amount
$407.8K
Amount sold
$407.8K
First sale
May 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.5MraisedMay 2022 · 26 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • David JordenExecutive Officer, Director
  • Scott PittmanDirector
  • Paul MintzDirector
  • C Eric WinzerDirector
  • Peter ClausenExecutive Officer
Offering amount
$3.5M
Amount sold
$3.5M
First sale
Apr 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$500KraisedJun 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • LAWRENCE S ATINSKYDirector
  • PAUL D MINTZDirector
  • PETER A CLAUSENExecutive Officer
  • DAVID E JORDENExecutive Officer, Director
  • SCOTT M PITTMANDirector
  • ERIC C WINZERDirector
Offering amount
$500K
Amount sold
$500K
Minimum investment
$500K
First sale
May 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Bioworld16 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Nuo Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Nuo Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update - BioSpacebiospace.com · Aug 2026Nuo Therapeutics Enters Amended $2 Million Loan Agreement and Issues Warrants – SEC Filing June 2026minichart.com.sg · Jun 2026

Frequently asked questions

What does Nuo Therapeutics do?
Nuo Therapeutics is a commercial-stage medical device company developing biodynamic therapies for wound care. Its flagship product, Aurix, is a hematogel that uses a patient's own platelets and plasma to promote healing.
How much funding has Nuo Therapeutics raised?
Nuo Therapeutics has disclosed $37.2M raised across 10 rounds.
Where is Nuo Therapeutics headquartered?
Nuo Therapeutics is headquartered in Houston, US.